Cohance Lifesciences Share: Bull Case vs Bear Case for 2026
NiveshIQ
NSE: COHANCE · Healthcare
Cohance Lifesciences Ltd.
₹440.20▼ ₹5.10 (-1.15%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on COHANCE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Cohance Lifesciences Ltd.
Cohance Lifesciences Limited, headquartered in Hyderabad, specializes in contract research, development, and manufacturing of new chemical entity (NCE) intermediates, active pharmaceutical ingredients (API), and specialty chemicals for the pharmaceutical, biotechnology, and chemical sectors. The company’s revenue mix is driven by small‑molecule APIs, advanced intermediates, antibody drug conjugates (ADC), and high‑purity oligonucleotide building blocks, with a reported FY24 revenue of ₹2,142 crore and net income of ₹106 crore. Recent strategic moves include a ₹50 crore investment in NJ Bio and Aruka Bio to bolster its ADC portfolio and the appointment of Krishna Sai T as Chief Information Officer to strengthen digital capabilities. Cohance’s global footprint spans India, the United States,
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,052 Cr -21.50% | ₹2,608 Cr +147.90% | ₹2,269 Cr -13.00% |
| EBITDA Margin | 38.40% | 30.52% | 20.32% |
| Net Profit | ₹301.00 Cr -26.80% | ₹483.00 Cr +60.50% | ₹150.12 Cr -68.90% |
| EPS | ₹11.81 | ₹19.14 | ₹4.69 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Cohance Lifesciences Share: Bull Case vs Bear Case for 2026
Cohance Lifesciences Share Price: Good Buy After Q1 FY27 Results?
🔒
+ 3 more stories about Cohance Lifesciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹422 Cr, PAT ₹-45 Cr, EPS ₹-0.63, EBITDA margin 3.2%. Growth context: revenue QoQ -31.8%, PAT QoQ -643.8%. Street verdict: inline, revenue surprise -4.8%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement as the primary near-term g...
FY26 (last completed FY): revenue ₹2, 269 Cr, PAT ₹150 Cr, EBITDA margin 20.3%, EPS ₹4.69. Year-on-year: revenue YoY -13...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for COHANCE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track COHANCE alongside your other holdings
Unlock full COHANCE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Cohance Lifesciences Ltd.?
NiveshIQ detects active intelligence signals for Cohance Lifesciences Ltd. (COHANCE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Cohance Lifesciences Ltd.?
Cohance Lifesciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,608,316.7L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.